This is a Phase Ib study to evaluate the safety, tolerability, and efficacy of TQB2928 in combination with third-generation EGFR TKIs in subjects with advanced non-small cell lung cancer, and to determine the recommended Phase II dose (RP2CD).
Age: 18-75 years; Eastern Cooperative Oncology Group (ECOG) score: 0-1; Expected survival of more than 3 months；
Locally advanced or metastatic NSCLC diagnosed by histology or cytology
The major organs are functioning well；
Negative serum pregnancy test within 7 days prior to the first dose and must be a non-lactating subject, female and male subjects of childbearing potential should agree to use contraception for the duration of the study and for 6 months after the end of the study；
Current concomitant presence of other malignancies within 5 years prior to the first dose;
Unresolved toxicity above CTCAE Grade 1 due to any prior anti-tumor therapy;
Significant surgical treatment, biopsy, or significant traumatic injury within 28 days prior to the first dose;
Long-term unhealed wounds or fractures;